Details of Disease

General Information of Disease (ID: DISSMOTT)

Disease Name Corticobasal degeneration
Synonyms
cortico-basal ganglionic Degeneration (CBGD); cortical-basal ganglionic degeneration; corticodentatonigral degeneration with neuronal achromasia; corticobasal syndrome; CBGD; cortical basal ganglionic degeneration; corticobasal degeneration
Disease Class 8A00: Parkinsonism
Definition A progressive neurodegenerative condition affecting the cerebral cortex and basal ganglia. The disorder is characterized by varying degrees of cognitive and motor impairment.
Disease Hierarchy
DIS6SVEE: Syndromic disease
DISUMR0A: Cerebral degeneration
DISSMOTT: Corticobasal degeneration
ICD Code
ICD-11
ICD-11: 8A00.1Y
Expand ICD-11
'8A00.1Y
Disease Identifiers
MONDO ID
MONDO_0022308
MESH ID
D000088282
UMLS CUI
C0393570
MedGen ID
95979
SNOMED CT ID
18842008

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID29334795-Compound-21 DMTOA1Q Patented Small molecular drug [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 4 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CIT TT3BKTU moderate Genetic Variation [2]
MOBP TTYUK4F Strong Genetic Variation [3]
MSMB TTYH1ZK Strong Biomarker [4]
TARDBP TT9RZ03 Strong Genetic Variation [5]
------------------------------------------------------------------------------------
This Disease Is Related to 9 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BPIFA2 OTLFSDZD Strong Biomarker [4]
PSPH OTV1PVAX Strong Biomarker [4]
PSPN OT54LLZJ Strong Biomarker [4]
REG1A OTMHUH1D Strong Biomarker [4]
RIDA OTW4098I Strong Biomarker [4]
SCRN1 OTELM5C2 Strong Biomarker [6]
SOS1 OTTCWXC3 Strong Genetic Variation [3]
SPPL2C OTUTY2ED Strong Genetic Variation [3]
STXBP3 OTTTYMAQ Strong Biomarker [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DOT(s)

References

1 Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
2 Combined visual and semi-quantitative assessment of (123)I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.Neurol Sci. 2017 Jul;38(7):1187-1191. doi: 10.1007/s10072-017-2936-3. Epub 2017 Apr 7.
3 Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.
4 Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms.PLoS One. 2017 Feb 16;12(2):e0172145. doi: 10.1371/journal.pone.0172145. eCollection 2017.
5 Atypical clinical features associated with mixed pathology in a case of non-fluent variant primary progressive aphasia.Neurocase. 2019 Feb-Apr;25(1-2):39-47. doi: 10.1080/13554794.2019.1609522. Epub 2019 Apr 29.
6 Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer's disease and not in other tauopathies.Acta Neuropathol Commun. 2019 Dec 3;7(1):195. doi: 10.1186/s40478-019-0848-6.